Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ENROLLING BY INVITATION
NCT06544109
PHASE2/PHASE3
Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
Sponsor: The First Affiliated Hospital of Soochow University
View on ClinicalTrials.gov
Summary
This study is to assess the efficacy and safety of venetoclax for prevention of DS in APL patients undergoing ATRA/ATO induction regimen.
Official title: Venetoclax for Prevention of Differentiation Syndrom (DS) in Acute Promyelocytic Leukemia (APL) Patients : An Open-lable, Single-arm, Multicenter, Phase Ⅱ Clinical Trail
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
98
Start Date
2023-08-01
Completion Date
2028-08-01
Last Updated
2024-08-09
Healthy Volunteers
No
Conditions
Interventions
DRUG
venetoclax
patients in whom the WBC counts increased to more than 2 × 109/L received Venetoclax
Locations (1)
Qiu huiying
Suzhou, Jiangsu, China